Tags

Type your tag names separated by a space and hit enter

Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone.
Allergy Asthma Proc. 2011 Mar-Apr; 32(2):127-36.AA

Abstract

This 52-week study was designed to assess the safety and efficacy of fluticasone propionate/salmeterol combination (FSC) 250/50 micrograms versus fluticasone propionate (FP) 250 micrograms in subjects with persistent asthma symptomatic on open-label FP 100 micrograms. The primary objective of this study was to show that FSC 250/50 micrograms was superior to FP 250 micrograms at increasing pulmonary function as measured by forced expiratory volume in 1 second over a 52-week treatment period. A secondary objective was to compare the rate of asthma attacks defined as (1) a sustained 2-day decrease in morning peak expiratory flow or increase in albuterol use for 2 consecutive days, (2) an asthma exacerbation requiring systemic corticosteroids, or (3) an unscheduled clinic or hospital visit for acute asthma symptoms. Three hundred six subjects received FSC 250/50 micrograms and 315 subjects received FP 250 micrograms. Both treatments were administered twice daily. Treatment with FSC 250/50 micrograms resulted in a significant improvement in lung function compared with FP 250 micrograms (p < 0.001). Additionally, treatment with FSC 250/50 micrograms resulted in a reduction in the rate of exacerbations of asthma (i.e., requiring systemic corticosteroids or unscheduled urgent care intervention) compared with FP 250 micrograms (0.170 versus 0.273, respectively; p = 0.017). There was no differentiation between treatments for less severe attacks of asthma. FSC 250/50 micrograms showed consistently greater improvement in lung function, symptom control, and decreased albuterol use. In addition, FSC 250/50 micrograms-treated subjects experienced fewer severe asthma exacerbations than subjects treated with FP 250 micrograms.

Authors+Show Affiliations

National Jewish Health, Denver, Colorado, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21189151

Citation

Katial, Rohit K., et al. "Long-term Treatment With Fluticasone Propionate/salmeterol Via Diskus Improves Asthma Control Versus Fluticasone Propionate Alone." Allergy and Asthma Proceedings, vol. 32, no. 2, 2011, pp. 127-36.
Katial RK, Bernstein D, Prazma CM, et al. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc. 2011;32(2):127-36.
Katial, R. K., Bernstein, D., Prazma, C. M., Lincourt, W. R., & Stempel, D. A. (2011). Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy and Asthma Proceedings, 32(2), 127-36. https://doi.org/10.2500/aap.2011.32.3426
Katial RK, et al. Long-term Treatment With Fluticasone Propionate/salmeterol Via Diskus Improves Asthma Control Versus Fluticasone Propionate Alone. Allergy Asthma Proc. 2011 Mar-Apr;32(2):127-36. PubMed PMID: 21189151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. AU - Katial,Rohit K, AU - Bernstein,David, AU - Prazma,Charlene M, AU - Lincourt,William R, AU - Stempel,David A, Y1 - 2010/12/28/ PY - 2010/12/30/entrez PY - 2010/12/30/pubmed PY - 2011/10/1/medline SP - 127 EP - 36 JF - Allergy and asthma proceedings JO - Allergy Asthma Proc VL - 32 IS - 2 N2 - This 52-week study was designed to assess the safety and efficacy of fluticasone propionate/salmeterol combination (FSC) 250/50 micrograms versus fluticasone propionate (FP) 250 micrograms in subjects with persistent asthma symptomatic on open-label FP 100 micrograms. The primary objective of this study was to show that FSC 250/50 micrograms was superior to FP 250 micrograms at increasing pulmonary function as measured by forced expiratory volume in 1 second over a 52-week treatment period. A secondary objective was to compare the rate of asthma attacks defined as (1) a sustained 2-day decrease in morning peak expiratory flow or increase in albuterol use for 2 consecutive days, (2) an asthma exacerbation requiring systemic corticosteroids, or (3) an unscheduled clinic or hospital visit for acute asthma symptoms. Three hundred six subjects received FSC 250/50 micrograms and 315 subjects received FP 250 micrograms. Both treatments were administered twice daily. Treatment with FSC 250/50 micrograms resulted in a significant improvement in lung function compared with FP 250 micrograms (p < 0.001). Additionally, treatment with FSC 250/50 micrograms resulted in a reduction in the rate of exacerbations of asthma (i.e., requiring systemic corticosteroids or unscheduled urgent care intervention) compared with FP 250 micrograms (0.170 versus 0.273, respectively; p = 0.017). There was no differentiation between treatments for less severe attacks of asthma. FSC 250/50 micrograms showed consistently greater improvement in lung function, symptom control, and decreased albuterol use. In addition, FSC 250/50 micrograms-treated subjects experienced fewer severe asthma exacerbations than subjects treated with FP 250 micrograms. SN - 1539-6304 UR - https://www.unboundmedicine.com/medline/citation/21189151/Long_term_treatment_with_fluticasone_propionate/salmeterol_via_Diskus_improves_asthma_control_versus_fluticasone_propionate_alone_ L2 - https://www.ingentaconnect.com/openurl?genre=article&amp;issn=1088-5412&amp;volume=32&amp;issue=2&amp;spage=127&amp;aulast=Katial DB - PRIME DP - Unbound Medicine ER -